Glaxo reaches $150 million settlement in nasal spray litigation
(Reuters) - British drugmaker GlaxoSmithKline Plc has reached a $150 million preliminary settlement with U.S. drug wholesalers who claimed the company improperly delayed entry to the market of generic alternatives to its nasal spray Flonase, according to court documents.
The settlement was reached with, among others, AmerisourceBergen Corp, Cardinal Health Inc, and McKesson Corp, who maintained that Glaxo had abused the citizen's petition process to maintain a market monopoly and overcharge for the spray by restricting access to less expensive generic versions.
The preliminary settlement was approved by the United States District Court for the Eastern District of Pennsylvania.
(Reporting By Toni Clarke; Editing by Gerald E. McCormick)
- Atheists face death in 13 countries, global discrimination: study
- Missouri executes man for killing good Samaritan motorist in 1994
- Focus turns to Thai military, anti-government protesters tell them to pick sides |
- Mandela signer hits back: I'm sign language champion |
- Google executives' planes saved millions in costs due to error - NASA
Time magazine named Pope Francis as its Person of the Year, crediting him with shifting the message of the Catholic Church. Slideshow